Healthcare
Live Price
Offline$29.12
-0.34% today
1Y Change
+70.08%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
STAAR Surgical Company (STAA) is a Healthcare stock with a market cap of $1.35B and listed on NASDAQ. The stock last traded around $29.12 and up 70.1% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -23.7%, EPS growth of -295.1%, a dividend yield of 0.0%. What stands out right now is revenue -23.7%, EPS -295.1%, free cash flow -422.2% with operating margin -33.3% and ROIC -19.5%. Valuation sits in the middle of the pack at price/sales 5.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STAA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STAA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STAA Max Drawdown
-43.65%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STAA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$230.5M
-19.0% YoY
FY Net Income
$27.5M
-30.6% YoY
Free Cash Flow
$30.3M
+72.2% YoY
Revenue Growth
-23.7%
EPS Growth
-295.1%
Gross Margin
75.6%
Net Margin
-33.6%
Income statement
USD
| Metric | 2026 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 239M | 314M | 322M | 284M | 230M |
| Gross Profit | 177M | 240M | 253M | 223M | 179M |
| Operating Income | -46M | -13M | 28M | 44M | 33M |
| EBITDA | -37M | -6M | 33M | 48M | 37M |
| Net Income | -80M | -20M | 21M | 40M | 28M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2026 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 153M | 144M | 183M | 86M | 200M |
| Total Assets | 462M | 510M | 489M | 419M | 346M |
| Total Liabilities | 117M | 112M | 103M | 83M | 87M |
| Shareholder Equity | 344M | 397M | 386M | 336M | 259M |
| Total Debt | 38M | 39M | 36M | 31M | 32M |
| Net Debt | -115M | -105M | -147M | -55M | -168M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
44M
+23.1% YoY
Capital Expenditures
14M
+24.6% YoY
Free Cash Flow
30M
+72.2% YoY
Key ratios
Gross Margin
75.6%
Operating Margin
-33.3%
Net Margin
-33.6%
ROE
-23.2%
Debt / Equity
0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.